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Background: Zingiber spectabile, commonly known as Beehive Ginger, is used as an 
ethnobotanical plant in many countries as an appetizer or to treat stomachache, toothache, 
muscle sprain, and as a cure for swelling, sores and cuts. This is the first report of isolation of 
Streptomyces strain from the root of this plant. Strain Universiti Kebangsaan 25 (SUK 25) has a 
very high activity to produce secondary metabolites against methicillin-resistant Staphylococcus 
aureus (MRSA), which is associated with high morbidity and mortality rates due to acquired 
multidrug resistance genes and causes medication failure in some clinical cases worldwide. 
Phylogenetic analysis based on the 16S ribosomal RNA gene sequence exhibited that the most 
closely related strain was Streptomyces omiyaensis NBRC 13449T (99.0% similarity).
Aim: This study was conducted to carry out the extraction, identification, and biological evalu-
ation of active metabolites isolated from SUK 25 against three MRSA strains, namely, MRSA 
ATCC 43300, MRSA ATCC 33591, and MRSA ATCC 49476.
Materials and methods: The production of secondary metabolites by this strain was opti-
mized through Thronton’s media. Isolation, purification, and identification of the bioactive 
compounds were carried out using reversed-phase high-performance liquid chromatography, 
high-resolution mass spectrometry, Fourier transform infrared, and one-dimensional and two-
dimensional nuclear magnetic resonance.
Results: During screening procedure, SUK 25 exhibited good antimicrobial potential against 
several strains of MRSA. The best biological activity was shown from fraction number VII 
and its subfractions F2 and F3 with minimum inhibitory concentration values at 16 ฀µg/mL 
and 8 ฀µg/mL, respectively. These two subfractions were identified as diketopiperazine cyclo-
(tryptophanyl-prolyl) and chloramphenicol.
Conclusion: On the basis of obtained results, SUK 25 isolated from Z. spectabile can 
be regarded as a new valuable source to produce secondary metabolites against bacteria, 
especially MRSA.
Keywords: Zingiber spectabile, MRSA, SUK 25, cyclo-(tryptophanyl-prolyl), chloramphenicol, 
HR-MS, NMR
Introduction
Natural products are naturally derived metabolites and/or by-products from plants, ani-
mals, or microorganisms.1,2 Natural products, in particular from microbes, are important 
sources of novel compounds for pharmaceuticals. Approximately 300,000 plant species 
growing in unexplored area on the earth are host to one or more endophytes.3,4 One of 
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these plants is Zingiber spectabile (common name Beehive 
Ginger), a member of the ginger family, which is used as an 
ethnobotanical plant in many countries, especially in South-
East Asia. Ginger is used as a remedy ingredient to treat a 
wide range of diseases including cancer5 and arthritis,6,7 and 
it is also used as an antioxidant. It is used as an appetizer or 
to treat stomachache, toothache, muscle sprain, and as a cure 
for swelling, sores and cuts.8
The Streptomyces species is a Gram-positive, aerobic, 
and spore-forming bacteria belonging to the order Actino-
mycetales that belongs to the phylum Actinobacteria.9 It has 
a high DNA G-C content around 52%–70%.10–13 It is well 
known for its ability to produce secondary metabolites with 
diverse chemical structures and different activity against 
numerous pathogenic microorganisms. Several studies 
have reported that ฀~23,000 biologically active secondary 
metabolite compounds were produced by microorganisms, 
among which 10,000 of these compounds were produced by 
actinobacteria. This represents 45% of all bioactive microbial 
metabolites discovered. Streptomyces species alone produces 
around two-thirds of these compounds.14,15
Endophytic Streptomyces sp. Strain Universiti Kebangsaan 
(SUK 25) was isolated from the root of Z. spectabile plant.16 
It appeared to have a good inhibitory activity against 
methicillin-resistant Staphylococcus aureus (MRSA).17 This 
bacterium is the major cause of hospital-associated infections 
(HAI-MRSA), and the resistance is the result of a supple-
mental penicillin-binding protein (PBP2a) encoded by the 
chromosomal mecA gene.18,19 The development of pathogenic 
bacteria resistance against antibiotic has become a serious 
problem worldwide. From this view, attempts have been 
made to extract, identify, and evaluate the active metabolites 
from SUK 25 against MRSA, and two compounds, namely, 
cyclo-(tryptophanyl-prolyl), which is a type of cyclic dipep-
tides diketopiperazines (DKPs), and chloramphenicol (CAP) 
have been isolated from this strain. Cyclic dipeptides DKPs 
or 2,5-DKPs, also known as dipeptide anhydrides (DPKs), 
are relatively simple compounds. Therefore, they are among 
the most common peptide derivatives found in nature.20 DPKs 
have been known since the beginning of the 20th century. 
They are found endogenously in many organisms and in 
large amounts in some foods and beverages.21 DPKs are 
extensively gained by extraction from natural sources such 
as plants, animals, and some microorganisms or by means of 
synthetic methods.22 CAP (previously called chloromycetin) 
is an antibiotic belonging to the family of nitroaromatic 
compounds; it was reported as a broad-spectrum antibiotic 
produced by Streptomyces species.23 The aim of this study 
was to screen the antagonistic activity of Streptomyces 
SUK 25 isolated from the root of Z. spectabile against 
multidrug-resistant pathogen, MRSA.
Materials and methods
Plant specimen and extract preparation
This study carried out the isolation, identification, and purifi-
cation of active secondary metabolites from SUK 25, which 
were isolated from the root of the plant Z. spectabile. Root 
samples of Z. spectabile were collected in 2009 from Bukit 
Panchor Country Park, Penang Island, Northern Peninsular 
Malaysia (5.14฀°N latitude and 100.54฀°E). This plant was 
selected based on its ethnobotanical property. Specimen 
voucher number was given, and the plant sample was submit-
ted to Universiti Kebangsaan Malaysia Herbarium collection. 
The pure colonies of endophytic actinomycetes obtained were 
subcultures onto International Streptomyces Project 2 (ISP2) 
agar and incubated at 28฀°C.16 The production of secondary 
metabolites by SUK 25 was optimized through Thronton’s 
media with some modification.17,24
Chemicals and media
All the chemicals used for extraction, column chromatogra-
phy (CC), high-performance liquid chromatography (HPLC), 
and liquid chromatography–mass spectrometry (LC–MS) 
were HPLC grade purchased from EMD Millipore, Billerica, 
MA, USA; thin-layer chromatography (TLC) was performed 
on percolated plates (20฀×20 cm) silica gel 60-F
254
 purchased 
from EMD Millipore; and Sephadex LH20 was purchased 
from GE Healthcare Bio-Sciences AB, Uppsala, Sweden. 
Mueller Hinton Broth (MHB) and Mueller Hinton Agar 
(MHA) were purchased from Difco, France.
In vitro antibacterial activity
Primary screening (cross-streak plate method)
The antibacterial activity was carried out by cross-streak 
plate method as described by Williston et al25 and also by 
Alexander.26 A single streak line of the SUK 25 was made 
on nutrient agar and then incubated at 28฀°C for 7 days. The 
cultures of MRSA ATCC 43300, ATCC 33591, and ATCC 
49476 were standardized to 0.5 McFarland standards using 
sterile MHB, corresponding to the reading of 0.08–0.1 
at A
625
 and then streaked at right angles to the original 
streak of SUK 25 and incubated at 37฀°C. The diameter of inhi-
bition zone (IZ, mm) was measured after 24 hours. The control 
plate was also maintained without inoculating SUK 25.
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Secondary screening (disk diffusion assay method)
The crude extract from SUK 25 was subjected to second-
ary screening using disk diffusion assay method, in accor-
dance with the Clinical and Laboratory Standards Institute 
(CLSI) guidelines. MRSA ATCC 43300 was inoculated 
into 10 mL MHB and incubated at 37฀°C for 2–6 hours. 
Turbidity was standardized to 0.5 McFarland (CLSI, 2011). 
The crude extract (1 mg/mL) of SUK 25 was dissolved in 
10% methanol, and 30 ฀µg/disk was loaded on a blank disk 
(6 mm diameter; Whatman™, Gred AA; Sigma–Aldrich Co., 
St Louis, MO, USA) and then dried in the hood. After that, 
the disk was placed on the MHA already lawned with MRSA. 
This culture was incubated overnight at 37฀°C. After overnight 
culture, the IZ in millimeters was measured for each plate, 
and vancomycin (30 ฀µg/disk) (Thermo Fisher Scientific, 
Waltham, MA, USA) was used as a positive control.
Fermentation, production, and extraction of 
secondary metabolites
For isolation and identification of bioactive metabolites, 
the Streptomyces sp. SUK 25 was cultured on ISP2 agar 
media, followed by incubation at 28฀°C for 14 days. Then a 
few blocks of ISP2 media containing pure and good growth 
of SUK 25 were then transferred into 250 mL of modified 
Thronton’s medium is composed of (g/L) K
2
HPO
4
 1.0, KNO
3
 
0.5, MgSO
4
฀⋅2H
2
0 0.2, CaCl
2
฀⋅H
2
O 0.1, NaCl 0.1, FeCl
3
 0.01, 
asparagine 0.5, and glucose 1.5 instead of mannitol at pH 
7.4.24 Then it was incubated at 28฀°C for 3 days with a gentle 
shake at 140 rpm using an orbital shaker. An aliquot of 60 mL 
of spore suspension of SUK 25 was aseptically transferred 
into 600 mL of Thronton’s broth as seeded media. After 
12 days of incubation at 28฀°C, fermentation filtrates were 
extracted with three half-volumes of ethyl acetate (EtOAC), 
and the crude extracts were separated and dried using rotary 
evaporator at 40฀°C and 240 mbar.27
Phylogenetic tree full of 16S rDNA gene sequencing
DNA extraction
Genomic DNA was isolated according to Kieser et al,28 and the 
purity and concentration were determined using NanoDrop 
spectrophotometer. Polymerase chain reaction (PCR) was 
performed according to Coombs and Franco29 using two sets 
of gene primer, 27f (5฀′-AGAGTTTGATCMTGGCTCAG-3฀′) 
with 765r (5฀′-CTGTTTGCTCCCCACGCTTTC-3฀′) and 
704f (5฀′-CTGGCGGTGAAATGCGTAGA-3฀′) with 1492r 
(5฀′-AAGGAGGTGWTCCARCC-3฀′), and the PCR product 
was sent to 1st BASE for sequencing. Sequencing data were 
analyzed using software BioEdit Version 7 and compared 
to the GenBank databases (BLAST) and EzTaxon Biocloud. 
Phylogenetic tree was built using the software Molecular 
Evolutionary Genetics Analysis (MEGA4) using the 
neighbor-joining (NJ) method.30
Chemotaxonomy analysis of LL-diaminopimelic acid 
cell wall of SUK 25
Chemotaxonomy features were analyzed through a type of 
LL-diaminopimelic acid (DAP) cell wall as described by 
Staneck and Roberts.31 Fifteen milligrams of mycelia dry 
weight of SUK 25 grown in ISP2 for 14 days was added to 
1 mL of 6N hydrochloric acid, and vortexed and autoclaved 
for 15 minutes at 121฀°C. After cooling, the hydrolysate was 
filtered using a filter paper (Whatman no 1) before being 
taken to dryness in a heating block at 95฀°C. Then, 1 mL 
of dH
2
O was added, and these procedures were repeated 
for two times. The filtrate was evaporated to dryness in an 
oven overnight. After evaporation, 1 ฀µL of hydrolysate and 
0.01 M DAP standard (Sigma-Aldrich Co.) in 0.2 M NaOH, 
which contained both the meso- and L isomers, was spotted 
on cellulose aluminum plate (EMD Millipore). Descending 
chromatography was performed in the solvent system 
containing methanol:dH
2
O:6N HCl:piridin (80:26:4:10), 
respectively, sprayed with ninhydrin (0.2% in acetone), and 
heated at 100฀°C for 3 minutes to reveal the spot.
6HSDUDWLRQDQGSXULÀFDWLRQRIDQWLPLFURELDO
compounds by CC and TLC
Fractionations and purifications of the dry crude extract 
were carried out using reversed-phase open CC and TLC. 
A 700 mg dry crude extract was dissolved in 10 mL methanol. 
This mixture was then subjected to separation through size-
exclusion CC containing 150 mg Sephadex LH20, using 
column size 2฀×40 cm. Gradient elution started with 100% 
chloroform, and the polarity of methanol was increased until 
100% (100:0, 95:5, 90:10, 85:15, 80:20, 70:30, 60:40, 50:50, 
and 0:100 v:v). Further purification using silica gel column 
was carried out using column size 2฀×40 cm. After CC, the 
fractions were applied to TLC plate and developed using 
mixture of hexane, ethyl acetate, and methanol (4:4:2 v:v) 
as mobile phase. The separated compounds were visualized 
under short ultraviolet (UV) at h
254 nm
 (absorbance) and long 
wavelength UV at h
365 nm
 (fluorescence), and then sprayed 
with 10% H
2
SO
4
 in ethanol and heated at 80฀°C–100฀°C for 
10 minutes. The compounds that had similar R
f
 in TLC were 
mixed together.
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Bioautography on disk diffusion
Disk diffusion assay method for all fractions that were puri-
fied from open CC was carried out in order to test the activity 
of each fraction separately against MRSA ATCC 43300.
Determination of the minimum inhibitory 
concentration and minimum bactericidal 
concentration
The minimum inhibitory concentrations (MICs) of the 
compounds were determined according to the method 
described by the CLSI.32,33 Twofold serial dilutions of each 
fraction dissolved in 10% MeOH were made with MHB in a 
96-well microtiter plate to give concentrations ranging from 
0.12 ฀µg/mL to 1,000 ฀µg/mL. Fifty microliters of test bacte-
rial suspension was inoculated in each well to give a final 
concentration of 1฀×105 CFU/mL. Bacteria inoculum in MHB 
was used as a positive control, whereas the tested compounds 
in MHB were used as a negative control. Determination of 
minimum bactericidal concentrations (MBCs) was performed 
by inoculating 20 ฀µL of each dilution with apparent no bacte-
rial growth in MIC wells and streak on MHA plates. Then, the 
plates were incubated for 24 hours at 37฀°C. The presence of 
colonies was considered an evidence of bacteriostatic action, 
while the absence of colonies indicated bactericidal activity.
3XULÀFDWLRQRIFRPSRXQGVXVLQJUHYHUVHGSKDVH
high-performance liquid chromatography
The crude extract of each fraction isolated from open CC was 
analyzed using an Agilent 1200 HPLC system equipped with 
a C-18 column (4.6฀×250 mm, 5 ฀µm). The mobile phase con-
sisted of H
2
O:Acetonitrile (ACN) with 0.1% trifluoroacetic 
acid (TFA) added to both solvents, and a gradient elution step 
was applied as shown in Table S1. The flow rate was 1 mL/min 
with an injection volume of 30 ฀µL from 1 mg/mL, and the 
elution was monitored by the UV absorption at 210 nm, 
240 nm, and 360 nm. The preparative HPLC protocol was 
carried out as same as analytical HPLC, only the quantity of 
injection and flow rate was injected to C-18 separation column 
(size 22฀×150 mm, 5 ฀µm), where the flow rate was 10 mL/min 
with an injection volume of 100 ฀µL each time from 7 mg/mL. 
Fractions were collected from a fraction collector.
Structure determination of antimicrobial compounds
FT-IR spectrophotometer, optical rotation, and 
melting point
Fourier transform infrared (FT-IR) spectrophotometer 
(Spectrum one FTIR spectrometer, PerkinElmer Inc., Waltham, 
MA, USA) using potassium bromide (KBr) disk method was 
carried out to determine the absorption bands of compounds. 
Optical rotation was measured on an Autopol VI automatic 
polarimeter (Rudolph Research analysis, USA). Melting point 
was measured on Stuart (Bibby Scientific, UK).
Nuclear magnetic resonance
The structure of compounds was determined using nuclear 
magnetic resonance (NMR) spectroscopy FT–NMR spectro-
scopy 600 MHz with Cryoprobe AVANCE III (Berker, 
USA). The probe temperature was maintained at 298 K, and a 
standard 5 mm NMR tube was used. Four milligrams of puri-
fied solid compound was dissolved in 200 ฀µL MeOH-d
4
 (99.8 
atom% D; Sigma-Aldrich Co.). Experiments that included 
one-dimensional (1D) 1H, 13C and two-dimensional (2D) 
NMR as sequences used in structural elucidation involving 
correlation spectroscopy (COSY), nuclear overhauser effect 
spectroscopy, and heteronuclear multiple-bond correlation 
spectroscopy (HMBC) were carried out to Berker standard 
pulse sequences. 1H and 13C chemical shifts (฀δ) are expressed 
in parts per minute (ppm) relative to solvent peak (MeOH-d
4
: 
1H ` 5.18 ppm and 13C ` 47.7 ppm).
High-resolution mass liquid chromatographymass 
spectrometry (HR-MS)
HR-MS was performed on an Agilent 6410 triple quadrupole 
mass spectrometer (Agilent Technologies, Santa Clara, 
CA, USA) equipped with an electrospray ionization inter-
face negative mode coupled to an Agilent 1200 HPLC 
(Agilent Technologies). Column Agilent Zorbax Eclipse 
Plus (150฀×2.1 mm, 5 ฀µm) HR-MS (Agilent Technologies) 
was used with column temperature 30฀°C, flow rate was 
0.3 mL/min, injection volume was 20 ฀µL, and mobile phase: 
pH 8.5 H
2
O (A) and acetonitrile (B). The retention time (R
T
) 
was measured in minutes. The flow rate was as shown in 
Table S1.
Statistical analysis
Statistical analysis of the data was performed using SPSS. 
One-way analysis of variance complemented by Tukey’s 
post hoc test was performed, and all data were reported as 
the mean ฀± standard deviation of the mean. All values were 
considered significant at P0.05.
Results
The present work describes a comprehensive methodol-
ogy for the screening, purification, and characterization of 
bioactive secondary metabolites isolated from endophytic 
Streptomyces SUK 25.
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Screening for antibacterial activity
Primary screening
Primary screening of SUK 25 was carried out to determine 
the potential of this strain to production of antimicrobial 
secondary metabolites against MRSA. SUK 25 showed 
good activity against MRSA ATCC 43300, MRSA ATCC 
33591, and MRSA ATCC 49476 as a primary screening. The 
distance between the edge of the tested bacterial growth and 
the SUK 25 bacterial growth was measured and recorded in 
millimeters. The IZ was 12 mm from the streaked right angle 
to the original streak of SUK 25 as shown in Figure S1.
Secondary screening by disk diffusion assays
SUK 25 was subjected to secondary screening using a sterile 
disk 6 mm in diameter; 30 ฀µg/disk of either compounds isolated 
from SUK 25 or vancomycin was used as a positive control. The 
plates were incubated at 37฀°C overnight. The mean diameters 
of triplicate samples of IZ were 20฀±1.2 mm and 18฀±1.3 mm for 
crude extract and vancomycin, respectively. The effect of this 
fraction was larger than vancomycin as shown in Figure S2.
Bioautography
The results of bioautography using the disk diffusion method of 
purified fractions from CC against MRSA are listed in Table 1. 
Thirteen fractions were isolated. Only fraction numbers I, II, 
and VII using chloroform (CHCl
3
) as an eluting solvent revealed 
activity against MRSA ATCC 43300 with a diameter of IZ 
at 14 mm, 15 mm, and 22 mm, respectively. However, only 
fraction numbers IX and X showed activity when MeOH was 
used as an elution solvent; the diameter of IZ was at 13 mm and 
14 mm, respectively, as shown in Table 1 and Figure S3.
Determination of the MIC and MBC
MIC is defined as the lowest concentration of an antimicro-
bial compound that inhibited the visible growth of a sensitive 
stain after the appropriate incubation period. MICs of all frac-
tions are presented in Table 1. MICs of fraction numbers VII, 
F2, F3, and vancomycin against MRSA ATCC 43300 were 
8 ฀µg/mL, 16 ฀µg/mL, 8 ฀µg/mL and 2 ฀µg/mL, respectively.
MBC was recorded as the lowest extract concentration, 
killing 99.9% of the bacterial inoculum after 24 hours incuba-
tion at 37฀°C. The MBCs of all active fractions were in the range 
of 32–128 ฀µg/mL. MBCs of fraction numbers VII, F2, and F3, 
standard CAP, and vancomycin were 64 ฀µg/mL, 32 ฀µg/mL, 
64 ฀µg/mL, 64 ฀µg/mL, and 4 ฀µg/mL, respectively. The MICs 
and MBCs of all active fractions are shown in Table 1. 
From the bioautography, MICs, MBCs, and preparative 
HPLC results, fraction number VII (including subfractions F2 
and F3) was selected for further analysis, where these subfrac-
tions exhibited strong anti-MRSA biological activity.
Phylogenetic tree of 16S rDNA 
sequences of SUK 25
Genomic DNA was extracted, and the 16S ribosomal RNA 
(rRNA) gene sequence was amplified by PCR using universal 
bacterial 16S rRNA gene primers as described.29 SUK 25 isolate 
sequences were compared with isolates in GenBank with Blast N 
software through the website www.ncbi.nlm.nih.gov. Sequences 
Table 1,VRODWLRQDQGSXULÀFDWLRQGHWDLOVRIVHFRQGDU\PHWDEROLWHFRPSRXQGVGLDPHWHURILQKLELWLRQ]RQH0,&YDOXHV฀µg/mL), and 
MBC values (฀µg/mL) of active fractions against MRSA ATCC 43300
Fraction number Weight (mg) IZ (mm) MIC (*g/mL) MBC (*g/mL)
FI 30 14 16 128
FII 51 15 8 32
FIII 45   
FIV 43   
FV 59   
FVI 32   
FVII 29 22 8 64
FVII-F2 11 15 16 32
FVII-F3 13 16 8 64
FVIII 77   
FIX 26 13 16 128
FX 24 14 16 128
FXI 51   
FXII 65   
FXIII 64   
Vanco  18 2 4
Abbreviations: MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; MRSA, methicillin-resistant Staphylococcus aureus; ATCC, American 
Type Culture Collection; , no activity; IZ, inhibition zone; Vanco, vancomycin (30 ฀µg/mL).
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were aligned and edited using Bioedit software  Version 7. 
Phylogenetic analysis was performed using MEGA 4.0 software 
to generate phylogenetic trees. The results showed that SUK 25 
(1,450 nucleotides) is closely related to Streptomyces omiyaensis 
NBRC 13449T with 99% similarities (Figure 1).
Chemotaxonomy analysis of DAP cell 
wall of SUK 25
For TLC analysis, all the triplicate samples of SUK 25 strains 
were found to support the identification they obtained in the 
DAP isomer, chromatographically similar to the standard 
from Sigma-Aldrich Co. The DAP spots were seen as gray-
green fading to yellow, with the L-DAP isomer moving 
ahead of the meso isomer with hydrolysates; amino acid 
spots appeared purple or red and migrated ahead of the DAP 
spot31 as shown in Figure 2.
Chemical characterization of isolated 
compounds
Analytical and preparative HPLC, melting point, optical 
rotations, and HR-MS
Different separation techniques such as TLC, CC, analytical 
and reversed-phase high-performance liquid chromatography 
(RP-HPLC), melting point, optical rotations, FT-IR, and 
HR-MS were carried out to obtain and identify the fraction 
FVII, which yielded two subfractions, namely, compound 
(F2) and compound (F3). HPLC purification peak is shown 
in Figures S3 and S4.
Compound F2: cyclo-(L-tryptophanyl-L-prolyl) (3S, 8aR)-3-
(1H-indol-3ylmethyl) hexahydropyrrolo [1, 2-a] pyrazine-1, 
4-dione
Analytical HPLC of this fraction showed R
T
 at 11.64 minutes 
with a UV absorbing band at 254 nm, by using RP-HPLC 
method as shown in Figure S1. The F2 was isolated as a 
colorless solid, gave a dark red coloration with anisaldehyde/
sulfuric acid, and became pink with Ehrlich’s reagent and 
blue with chlorine/o-anisidine as indication of a peptide with 
R
f
 ฀=0.47 (CHCl
3
:MeOH; 95:5, v/v). The melting point of 
this fraction was between 165฀°C–168฀°C. The optical rota-
tions of this compound [฀α]25 C (0.001 g) was (฀−46.819฀°) 
using methanol as a solvent. The m/z value of this compound 
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Figure 1 Neighbor-joining tree showing the relationship of strain SUK 25 based on a 16S rRNA gene sequences (1,450 nucleotides with closely related members of the 
genus Streptomyces omiyaensis NBRC 13449T and Kitasatospora setae KM-6054 as the outgroup).
Abbreviations: SUK 25, strain Universiti Kebangsaan 25; rRNA, ribosomal RNA.
?????
?????
?????
??
????
? ? ? ?
Figure 2 TLC analysis of whole-cell hydrolysate of SUK 25.
Notes: All triplicate test strains of SUK 25 contain LL-DAP isomers (2, 3, and 4) 
similar in chromatographic behavior to that produced by the standard marker (1). 
The amino acid spots appeared purple or red and migrated up to DAP.
Abbreviations: TLC, thin-layer chromatography; SUK 25, strain Universiti Kebangsaan 
25; DAP, diaminopimelic acid.
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was 283.1321 [M฀+] at R
T
 6.63 minutes. The mass spectrum 
confirmed the structure based on the proposed fragmentation 
mechanism pathway. The molecular formula is C
16
H
17
N
3
O
2
. 
The 1H and 13C signals were assigned on the basis of chemi-
cal shifts, spin–spin coupling constants, splitting patterns, 
and signal intensities. The 1H NMR spectrum of F2 showed 
a broad 1H singlet at ฀δ 8.20 characteristic for an NH of an 
indole moiety, five aromatic protons at ฀δ 7.59, 7.40, 7.24, 
7.14 (m, 2H) confirming the indole skeleton substituted at 
3-position. In the aliphatic region, another broad 1H singlet of 
an acidic proton at ฀δ 5.75 due to NH of an amide, two oxygen-
ated or aminated methines at ฀δ 4.39 (dd) and 4.08 (t), three 
different resonances each of 1H, 2H, and 1H, respectively, at 
฀δ 3.76 (dd), 3.64 (m), and 2.97 (dd) were seen. In addition, 
three multiplets of 4H between ฀δ 2.36 and 1.90 were repre-
sentative for two methylene groups. The 13C NMR spectrum 
exhibited four signals in the region between 22.48 and 
45.33 ppm attributed to four CH
2
. The rest of the spectrum dis-
played 12 signals, among them seven were CH (123.4–110.0) 
and five were quaternary carbons (169.5–111.6), two of them 
belong to amide carbonyls (169.5 and 165.7) as shown in 
Figure S3. The prediction data from NMR suggested that 
this subfractionation is similar with the NMR data of cyclo-
(L-tryptophanyl-L-prolyl), also known as brevianamide F.34 
1H and 13C NMR data are shown in Table 2 and Figure 3. 
A search in AntiBase revealed that F2 was known as L,L- 
cyclo-(tryptophanyl-prolyl) or cyclo-(L-Trp-L-Pro), which 
was further confirmed by comparison with the previous lit-
erature by Kobayashi and Palumbo35 and Amar et al.36
Compound F3: CAP 2,2-dichloro-N-[(1R, 2R)-2-hydroxy-
1-(hydroxymethyl)-2-(4-nitrophenyl) ethyl]-acetamide
Analytical HPLC of this fraction showed R
T
 at 14.3 minutes 
with UV absorbing band at 273 nm as shown in Figures S1 
and S2. By using RP-HPLC, the F3 was isolated as a 
grayish-white or yellowish-white crystalline powder, gave 
a dark red coloration with anisaldehyde/sulfuric acid, 
and became pink with Ehrlich’s reagent and blue with 
chlorine/o-anisidine as indication of a peptide with R
f
 ฀=0.75 
(CHCl
3
:MeOH; 95:5, v/v). The melting point of this fraction 
was between 150฀°C and 152฀°C. The optical rotation of this 
compound [฀α]25 C (0.001 g) was ฀+31.493฀°, whereas the 
optical rotation of standard CAP [฀α]25 C (1 g) was ฀+17.496฀° 
using ethyl acetate. F3 and standard CAP were character-
ized by HR-MS spectra using negative ionization mode due 
to the better response in relation to the positive ionization 
mode. The m/z value of this compound was 322 [M−H]– at 
R
T
 11.9 minutes. The mass spectrum confirmed the structure 
based on the proposed fragmentation mechanism pathway. 
The molecular formula is C
11
H
12
C
l2
N
2
O
5
 and was sup-
ported by 1H and 13C NMR data as shown in Table 3 and 
Figures S4–S8. The 1H and 13C signals were assigned on 
the basis of chemical shifts, spin–spin coupling constants, 
splitting patterns, and signal intensities and by using 1H–1H 
COSY, 1H–13C heteronuclear single quantum coherence 
(HSQC), and 1H–13C HMBC experiments. The 1H and 13C 
chemical shifts of compound FVII-F3 are given in Table 3 
and Figure 4. Chemical shifts were calibrated internally 
against the residual signal of the solvent in which the sample 
was dissolved in MeOH-d
4
 with ฀δ H at 5.18 and C at 47.7. 
1H NMR (600 MHz, MeOH-d
4
) of FVII-F3 showed 12 pro-
tons, at 8.3 (2H, m, aromatic-H), 7.67 (2H, m, aromatic-H), 
Table 2 1D-1H NMR and 13C NMR spectrum data of FVII-F2 
cyclo-(L-tryptophanyl-L-prolyl)
Number ` H (J in Hz) ` 13C
1  
2 3.76 Ha, 2.97 Hb 28.19 (CH
2
-2)
3 2.361.90 22.48 (CH
2
-3)
3a  
4 2.361.90 26.76 (CH
2
-4)
5 4.08 59.18 (CH-5)
6  165.68 (Cq-6)
7 5.75 NH 
7a  
8 4.39 54.60 (CH-8)
9  169.48 (Cq-9)
10 3.64 45.33 (CH
2
-10)
11  111.61 (Cq-11)
12 7.617.14 123.39 (CH-12)
13 8.20 NH 
14  136.81 (Cq-14)
15  126.85 (Cq-15)
16 7.617.14 122.81 (CH-16)
17 7.617.14 120.04 (CH-17)
18 7.617.14 118.55 (CH-18)
19 7.617.14 109.99 (CH-19)
Note:  indicates no hydrogen or carbon attached.
Abbreviations: 1D, one-dimensional; NMR, nuclear magnetic resonance; delta, `, 
chemical shift scales in NMR; J, coupling constants in hertz.
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Figure 3 The chemical structure elucidation of cyclo-(L-tryptophanyl-L-prolyl).
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6.3 (1H, s), 5.18 (1H, s), 4.16 (1H, s), and 3.62–3.8 (2H, 
dd, J฀=6.0 Hz; 12.0 Hz). The 13C and HSQC spectra show 
eleven carbon signal peaks at 165.2, 148.6, 126.9, 126, 
150.2, 69.9, 57.10, and 60.80 (six aromatic carbons). The 
2D 1H–1H and 1H–13C experiments, and especially the long-
range 1H–13C couplings observed in the HSQC, COSY, and 
HMBC spectrum as shown in Figures S9–S11, permitted 
the connectivity between all the groups of the molecule to 
be established.
Fourier transform infrared spectroscopy
The FT-IR spectrum for the two compounds exhibited 
absorption bands, which indicated the presence of NH, 
aromatic C–H stretching, carbonyl group, and C฀=O groups in 
the structure, respectively, at V
max
 3,345 cm฀−1 and 3,257 cm฀−1 
(NH
2
 group and O–H stretching), 2,901 cm฀−1 (aromatic C–H 
stretching), 1,684 cm฀−1 (carbonyl group), 1,343 cm฀−1 (C–H 
bending), 652 cm฀−1 (carbon-chlorine bonds), 1,092 and 1,121 
(C–N stretch), and 972 cm฀−1 (H–C–H – asymmetric stretch) 
as shown in Table S2 and Figures S12 and S13.
Discussion
The aim of this study was to screen the antagonistic activity 
of Streptomyces SUK 25 isolated from roots of Z. spectabile 
against drug-resistant pathogen, MRSA. The primary screen-
ing results indicated that SUK 25 has the ability to produce 
secondary metabolites in nutrient agar, which diffused 
through the agar that prevented and inhibited the growth of 
three MRSA strains, namely, MRSA ATCC 43300, MRSA 
ATCC 33591, and MRSA ATCC 49476. The IZ was ฀~12 mm 
from the edge of growth of SUK 25. A secondary screening 
using disk diffusion method had 20 mm IZ against MRSA 
ATCC 43300, which is similar with previous study conducted 
by Morakchi et al.37 Cho et al38 also reported the antibacte-
rial activity of Streptomyces sp. CS392 against MRSA and 
vancomycin-resistant enterococci. Marine Streptomyces sp. 
VITBRK2 also has the ability to produce active secondary 
metabolites against MRSA and vancomycin-resistant entero-
cocci strains.39 Furthermore, strain Streptomyces MUSC 
135T, which was isolated from a soil sample collected from 
a mangrove forest located on the east coast of Peninsular 
Malaysia, exhibited a broad-spectrum bacitracin against 
MRSA ATCC BAA-44.40 In addition, Streptomyces sp. 
HUST012 was isolated from the stems of the medicinal 
plant Dracaena cochinchinensis Lour. This strain produced 
secondary metabolites, namely, SPE-B11.8 and SPE-B5.4, 
which showed antimicrobial activity against MRSA ATCC 
25923 with MIC 62.5 and 0.04, respectively.41
The results of the analysis translated through phylogenetic 
tree NJ method of 16S rRNA sequences of SUK 25. (1,450 
nucleotides) was closely related to several strains of Strep-
tomyces sp. from culture collections in the database NCBI 
GenBank. Analysis of 16S rRNA showed a similarity level of 
99% within S. omiyaensis NBRC 13449T, which was isolated 
from Omiya city in Japan and showed a potential activity to 
produce CAP.42 Chemotaxonomic analyses showed that the 
cell wall of strain SUK 25 contained DAP, indicating that it 
was of cell-wall type I.43 Production of secondary metabo-
lites by SUK 25 for large-scale fermentation was optimized 
through Thronton’s media at 12 days incubation with pH 7 
and aerated at 140 rpm as reported by Junaidah et al44 with 
some modification on incubation time from 7 days to 12 days 
according to the optimization of growth curve of SUK 25. 
From the results of bioautography, there were five active 
fractions against MRSA ATCC 43300. The most active 
fraction was the fraction number VII, which had a signifi-
cant IZ of 22 mm by disk diffusion assay compared to only 
Table 3 1D-1H NMR and 13C NMR spectrum data of FVII-F3 
chloramphenicol
Position ` H (J in Hz) ` C HMBC (H-C)
1  148.6 
2, 6 8.3 (2H) m 126.9 H6 (C-1, 4)
3, 5 7.67 (2H) m 126 H3 (C-1, 2, 7)
4  150.2 
7 5.18 69.9 H7 (C4, 5, 8, 9)
8 4.16 57.10 H8 (C-10)
9 3.623.8, 2H, dd, 
J฀=6.0 Hz; 12.0 Hz
60.80 
10  165.2 
11 6.3 66.0 (d, CH-Cl2) H11 (C-10)
Note:  indicates no hydrogen or carbon attached.
Abbreviations: 1D, one-dimensional; NMR, nuclear magnetic resonance; delta, `, 
chemical shift scales in NMR; J, coupling constants in hertz; HMBC, heteronuclear 
multiple-bond correlation.
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Figure 4 The chemical structure elucidation of chloramphenicol using 2D-NMR 
HMBC and COSY correlations of FVII-F3 compound.
Note: 1H13C HMBC correlation ฀→฀฀1H 1H COSY correlation.
Abbreviations: 2D-NMR, two-dimensional nuclear magnetic resonance; HMBC, 
heteronuclear multiple-bond correlation; COSY, correlations spectroscopy.
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18 mm of vancomycin at the same concentration of 30 ฀µg/
disk. Furthermore, two active compounds F2 and F3 were 
isolated from fraction number VII. Separation, purification, 
and isolation of fraction number VII and its subfractions in 
pure form were carried out using TLC, open CC, analytical 
and RP-HPLC, HR-MS, and FT-IR. Chemical structure 
elucidation was carried out by 1D and 2D NMR to confirm 
the structure of compounds. The first compound (F2) was 
isolated as cyclo-(L-tryptophanyl-L-prolyl), also known as 
brevianamide F, with m/z 283.1321 [M฀+] and molecular 
formula C
16
H
17
N
3
O
2
. It is a form of DKPs tryptophan–proline 
derivative. It has been described, isolated, and structurally 
characterized for the first time from Penicillium brevicom-
pactum.34 This compound has been reported by Mahmoud45 
and Amar et al.36 It has insecticidal properties46 and has been 
reported to possess nematocidal activity.47 Furthermore, it has 
anti-inflammatory properties,48 and the antibacterial activity 
of this compound has been recorded against Escherichia 
coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, 
S. aureus, Bacillus subtilis, and Streptococcus pneumonia.49,50 
It also has antimicrobial effect against Micrococcus luteus 
LB 14110 and S. aureus ATCC 6538 with IZ 14 mm.51 In 
this study, the IZ was 15 mm against MRSA ATCC 43300. 
It also found that this compound has antifouling potential 
activity and showed potent activity against larval settlement 
of Bugula neritina.52
The second compound (F3) was identified as CAP with 
m/z 322 and molecular formula C
11
H
12
Cl
2
N
2
O
5
,
 
which was 
reported by some of the previous studies by Pfenning et al53 
and Gantverg et al.54 Previously, CAP was obtained from 
Streptomyces venezuelae by Ehrlich et al,55 which was the 
first research that reported the isolation of the new CAP 
from a soil sample from Caracas, Venezuela. It was then 
isolated and identified by other researchers such as Smith 
et al56 and Umezawa et al.57 At the same time, in 1948, Okami 
reported ฀~14 strains of Streptomyces pheochromogenus 
var chloromyceticus that have the ability to produce this 
antibiotic. In addition, S. Omiyaensis, which was isolated 
from Omiya city, showed a potential activity to produce this 
antibiotic.42 Furthermore, Streptosporangium viridogriseum 
var kofuense isolated from the soil has the ability to produce 
CAP.58 The findings from this study were also similar to other 
previous studies by Mosher et al59 and Aouiche et al,60 where 
they isolated and identified CAP from Streptomyces lividans 
M252 and Saccharothrix sp. PAL54, respectively. This study 
compared the data from F3 with standard commercial CAP 
from Sigma-Aldrich Co. using FT-IR, HR-LC–MS, and 
NMR data and showed that all data were compatible for 
both of them. These findings confirmed that this fraction 
was similar to commercial CAP as shown in Figures S3–S6. 
This antibiotic has been designated as a broad-spectrum 
antibiotic effective against Gram-positive and Gram-negative 
bacteria.61 Its mode of action was reported as a potent protein 
inhibitor, which is inhibiting bacterial growth by binding to 
their 50S ribosomal subunit.62 However, several previous 
researchers found that this antibiotic has some side effects, 
such as aplastic anemia or reproductive/hepatotoxic effects, 
in human and animals.63,64 Therefore, the European Union 
has not authorized the use of this antibiotic in food-producing 
animals to protect public and animal health.65 Despite its 
side effects, it is still been used in the treatment of seri-
ous infections, such as meningitis, brain abscesses, severe 
Haemophilus influenzae infections, and typhoid fever.66 
This is because it has excellent cellular penetration, and it 
is extensively distributed in the body.67 In 1948, Woodward 
et al evaluated the effectiveness of CAP as a treatment for 
typhoid and paratyphoid fevers. All the patients in their trials 
responded well to this antibiotic, where the mortality rate of 
typhoid fever has been reduced from 20% to 1%, and the 
duration of fever decreased from 2–4 weeks to 4–5 days. 
It has provided the gold-standard against which other anti-
biotics have been compared at that time. The MICs of this 
antibiotic against Salmonella typhi were between 0.75 ฀µg/mL 
and 5 ฀µg/mL.68
The MIC and MBC values of F2 were equal to 16 ฀µg/mL 
and 32 ฀µg/mL, which were compatible with the previous 
study by Kumar et al.50 In addition, the MIC and MBC values 
of F3 were equal to 8 ฀µg/mL and 64 ฀µg/mL, respectively, 
which were compatible with the previous study by Fayyaz 
et al.69 In relation to the ratio of MBCs to MICs of the com-
pounds, it was 4 when F2 was used, which indicates that 
this compound has bactericidal effects that kill most of the 
bacteria,70 whereas this ratio was 4 when F3 was used, 
which indicates bacteriostatic effects of this compound 
that only inhibit the growth of bacterial cells but do not kill 
completely.71–73
Conclusion
This study identified two natural bioactive compounds, cyclo-
(L-tryptophanyl-L-prolyl) and CAP, from SUK 25 that were 
potent against MRSA. This indicates that this bacterium is 
a potential source for bioactive natural products in the phar-
macological industry against MRSA.
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